ANGO — Angiodynamics Cashflow Statement
0.000.00%
Last trade - 00:00- $287.59m
- $211.54m
- $303.91m
- 49
- 48
- 74
- 58
Annual cashflow statement for Angiodynamics, fiscal year end - May 31st, USD millions except per share, conversion factor applied.
2020 May 31st | 2021 May 31st | 2022 May 31st | 2023 May 31st | 2024 May 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 8-K |
| Standards: | USG | USG | USG | USG | — |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -167 | -31.5 | -26.5 | -52.4 | -184 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 159 | 25.5 | 14.8 | 31 | 122 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -28.5 | 9.07 | -21 | -7.03 | 14.4 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -14.6 | 24.1 | -7.19 | 0.078 | -28.2 |
| Capital Expenditures | -7.58 | -5.19 | -4.3 | -4.35 | -5.77 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -55.8 | -8.52 | -15 | -5.39 | 129 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -63.3 | -13.7 | -19.3 | -9.75 | 124 |
| Financing Cash Flow Items | -1.98 | 0 | 0 | -0.751 | -15 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -95.2 | -17 | 7.68 | 25.4 | -64.2 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -173 | -6.27 | -19.3 | 15.8 | 31.4 |